

Reference:	FOI.8951.22
Subject:	Intra-vitreous treatments in Ophthalmology
Date of Request:	19 May 2022

Requested:

- How many patients over the last 4 months (January to April 2022) have received the following anti-Vascular Endothelial Growth Factor (VEGF) treatments for any eye condition:
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Ranibizumab
- For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Ranibizumab
- Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:
 - Aflibercept
 - Bevacizumab
 - Dexamethasone
 - Ranibizumab
- Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:
 - Aflibercept
 - Bevacizumab
 - Dexamethasone
 - Ranibizumab

Response:

- Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that received the anti-VEGF treatments listed, during the period January to April 2022.

Treatment	Number of patients
Aflibercept	714
Bevacizumab	0
Brolucizumab	0
Dexamethasone	0
Ranibizumab	100

2. The UHB provides, within the table below, the number of first time patients that received the anti-VEGF treatments listed, during the period January to April 2022.

Treatment	Number of patients
Aflibercept	34
Bevacizumab	0
Brolucizumab	0
Dexamethasone	0
Ranibizumab	4

3. The UHB provides, within the table overleaf, the number of patients treated with the listed medications for Diabetic Macular Oedema (DMO), during the period January to April 2022.

Treatment	DMO
Aflibercept	100
Bevacizumab	0
Dexamethasone	0
Ranibizumab	14

4. The UHB provides, within the table below, the number of patients treated with the listed medications for Wet Age Related Macular Degeneration (WAMD), during the period May to August 2021.

Treatment	WAMD
Aflibercept	84
Bevacizumab	0
Dexamethasone	0
Ranibizumab	19